Parkinson’s Disease Therapeutics Market Size By Drug Class (Levodopa/Carbidopa, Dopamine Agonists, Adenosine A2A Antagonist, COMT Inhibitors, MAO-B Inhibitors, Glutamate Antagonist), By Route of Administration (Oral, Subcutaneous, Transdermal), By Patient (Adult, Pediatric), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2021 – 2027

Published Date: Jan 2021  |  Report ID: GMI2724  |  Authors: Sumant Ugalmugale, Rupali Swain

Report Format: PDF   |   Pages: 150   |   Base Year: 2020




Summary Table of Contents Industry Coverage Methodology

Industry Trends

Parkinson’s Disease Therapeutics Market valued at around USD 5.18 billion in 2020 and is projected to grow at more than 6.5% CAGR between 2021 and 2027. Growing environmental factors and genetic heredity have augmented the demand for Parkinson’s disease therapeutics. Rising aging population coupled with increasing prevalence of Parkinson’s disease is anticipated to stimulate the market growth. Growing funding in research and development will lead to development of novel therapeutics that will further contribute to the market expansion. Rising awareness among the population regarding effective therapeutics will increase the demand for Parkinson’s disease therapeutics.
 

Parkinson’s Disease Therapeutics Market Overview

Get more details on this report - Request Free Sample PDF
 

The rising prevalence of Parkinson’s disease has led to the development of effective Parkinson’s disease therapeutics. However, these are regulated by regulatory authorities including the U.S. Food and Drug Administration (USFDA). For instance, Parkinson’s disease patients being treated with levodopa/carbidopa experience “off” episodes. Therefore, in 2019, the USFDA granted approval of Nourianz (istradefylline) tablets that overcome the side effects of levodopa/carbidopa in adult patients suffering from Parkinson’s disease. In Europe, the licensing procedure for therapeutics to treat Parkinson’s disease is governed centrally by the European Medicines Agency (EMA).
 

The ongoing COVID-19 pandemic is an unprecedented public health concern. According to a recently published study, COVID?19 may worsen Parkinson’s disease by several mechanisms such as pharmacodynamics changes and systemic inflammatory responses. Thus, scientists across the globe are engaged in developing Parkinson’s disease therapeutics including amantadine to treat patient suffering from Parkinson’s disease, thereby maintaining a consistent demand for Parkinson’s disease therapeutics. However, the restrictions and diversion of resources precipitated by COVID?19 have led to inaccessibility of effective symptomatic treatment for Parkinson’s disease.
 

Rising aging population coupled with increasing prevalence of Parkinson’s disease will stimulate the demand for Parkinson’s disease therapeutics market. Parkinson’s disease (PD) is one of the most complex and common neurodegenerative disorders that primarily affects the aging population. Around 10 million people worldwide are presently living with Parkinson’s disease. As the disease progresses, the elderly patients experience cardinal clinical symptoms such as slowness, stiffness, limb tremor, postural instability among others. Hence, the treatment for the Parkinson’s disease focuses on maintaining the patient’s activity level and optimizing quality of life. Thus, owing to these attributes there is a high demand for effective therapeutics that will in turn propel the overall market revenue in the coming years.
 

Growing preference for catechol-O-methyltransferase (COMT) inhibitors will spur the Parkinson’s disease therapeutics market demand

COMT inhibitors segment is predicted to witness 8.8% growth rate till 2027 led by the high efficacy of Catechol-O-methyltransferase (COMT) inhibitors in alleviating the motor symptoms of Parkinson’s disease. COMT inhibitors have proven to be beneficial adjunct to levodopa (LD) therapy as they increased the bioavailability of LD and prolong the elimination of LD in Parkinson’s disease patients. The advantages associated with COMT inhibitors are essential to augment their utilization and demand.
 

Increasing adoption of oral route of administration will foster the market size

Oral segment in the Parkinson’s disease therapeutics market exceeded USD 3.41 billion in 2020 impelled by the factors such as pain avoidance, ease of ingestion, patient compliance and versatility to accommodate various types of drugs. Several dopamine agonists including Ropinirole and Pramipexole are administered through oral route of administration for increased clinical outcome. Thus, these factors are growing the preference for oral route of administration that will in turn propel the overall industry growth.
 

Rising in number of adults suffering with Parkinson’s disease will enhance the market growth

Parkinson Disease Therapeutics Market Size

Get more details on this report - Request Free Sample PDF
 

Parkinson’s disease therapeutics market for Adult patient segment accounted for USD 4.35 billion in 2020 propelled by the increasing prevalence of Parkinson’s disease in adults. According to a published article, in the U.S., in 2017, approximately 90,000 commercially insured adults between the age of 30 and 64 years were diagnosed with Parkinson’s disease. In addition, men are 1.5 times more likely to suffer from Parkinson’s disease than women.
 

Growing prevalence of Parkinson’s disease in North America will boost the regional growth

Global Parkinson’s disease therapeutics market

Get more details on this report - Request Free Sample PDF
 

U.S. Parkinson’s disease therapeutics market held more than 94% of revenue share in 2020 driven by high incidences of Parkinson’s disease in the country. It is the second-most common neurodegenerative disorder in the U.S. According to the National Institute of Health, approximately 1.2 million people in the U.S. are anticipated to have Parkinson’s disease by 2030. Several biopharmaceutical companies and research organizations are engaged in production of novel Parkinson’s disease therapeutics. For instance, in the U.S., more than 40 medicines are being developed for the treatment of Parkinson’s disease, many of which have gained fast track designation from the USFDA. Furthermore, well-established healthcare infrastructure and greater accessibility to therapeutics is contributing to the rising demand for Parkinson’s disease therapeutics.
 

UK Parkinson’s disease therapeutics market size was USD 198 million in 2020. According to the National Health Service (NHS), approximately 127,000 people in the UK are presently suffering from Parkinson’s disease. Rising burden of Parkinson’s disease management on healthcare systems of major countries in Europe including UK is stimulating the efforts by the government to increase the pace of R&D in Parkinson’s disease therapeutics. UK Parkinson’s Disease Consortium (UKPDC), is engaged in development of new hypothesis, explore disease mechanisms, and identification of new Parkinson’s disease therapeutics. Moreover, people suffering from Parkinson’s disease in the UK can apply for a Parkinson’s UK Grant up to USD 1,840. This factor is further contributing in the development and demand for Parkinson’s disease therapeutics.
 

Presence of strong market players implementing strategic initiatives will contribute to the market revenue

Some of the major companies operating in the Parkinson’s disease therapeutics market include Orion Corporation, Roche, AbbVie Inc., Acadia Pharmaceuticals, Amneal Pharmaceuticals, UCB, Teva Pharmaceutical among others. The market leaders are engaged in several strategic collaborations, mergers, partnerships, product launches and acquisitions in order to strengthen their industrial position. Additionally, the investments made by these participants is creating opportunities for global expansion of the market.
 

Parkinson’s disease therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments:

Market, By Drug Class, 2016 - 2027 (USD Million)

  • Levodopa/Carbidopa
  • Dopamine Agonist
  • Adenosine A2A Antagonist
  • COMT Inhibitors
  • MAO-B Inhibitors
  • Glutamate Antagonist
  • Others

Market, By Route of Administration, 2016-2027 (USD Million)

  • Oral
  • Subcutaneous
  • Transdermal
  • Others

Market, By Patient, 2016-2027 (USD Million)

  • Adult
  • Pediatric

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia

 

Frequently Asked Questions (FAQ) :

The global market for Parkinson’s disease therapeutics had reached USD 5.15 billion in 2020 and will expand at more than 6.5% CAGR up to 2027.
The market share from COMT inhibitors segment is anticipated to register about 8.8% CAGR between 2021-2027 owing to high efficacy provided to alleviate motor symptoms in Parkinson’s patients.
The industry share from the oral administration segment was more than USD 3.41 billion in 2020 and will grow due to the ease of ingestion, pain mitigation and better patient compliance.
The U.S. held more than 94% of North America Parkinson’s disease therapeutics industry in 2020 as it is the second most common neurodegenerative disease in the country.

Premium Report Details

  • Published Date: Jan 2021
  • Pages: 150
  • Tables: 180
  • Charts / Figures: 15
  • Companies covered: 15
  • Countries covered: 17

Get a report that explains COVID-19 impact on this market

Buy Now

Need a Discount? Get in touch with us for special pricing

Request Discount

 Connect with our sales team

Chat with us
We use cookies to enhance user experience. (Privacy Policy) X